Diagnostic efficacy of aneuploidy markers correlated with early onset preeclampsia. Issue 50 (16th December 2022)

• Record Type: Journal Article
• Authors: Pyeon, Seung Yeon; Kwon, Byung Su; Kim, Young Sun; Lee, Young Joo
• Is Part Of: Medicine. Volume 101:Issue 50(2022)
• Page Start: e32319
• Publication Date: 2022-12-16
• Subjects: alpha-fetoprotein -- aspirin -- human chorionic gonadotropin -- preeclampsia -- pregnancy-associated plasma protein A; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000032319
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Low-dose aspirin administration before 16 weeks of gestation can prevent preeclampsia (PE) more effectively. In order to determine if aspirin should be administered, this study aimed to investigate the predictive value of pregnancy-associated plasma protein A (PAPP-A) and aneuploidy markers for the onset period of PE. 1053 singleton pregnant women were included in the study, and serum PAPPA-A and aneuploidy markers were analyzed between 3 group (normotensive, late-onset PE, and early-onset PE). The utility of these markers for predicting early-onset preeclampsia (EOPE) was compared using each marker and their combination. Alpha-fetoprotein (AFP)/PAPP-A > 6.89 and human chorionic gonadotropin (hCG)/PAPP-A > 7.94 were associated with EOPE with a positive likelihood ratio (LR) (6.52, 95% confidence interval [CI] 4.9–7.1), and (5.77, 95% CI 3.9–6.4). The combination of markers could predict EOPE more accurately compared to the single markers. AFP/PAPP-A > 6.89 and hCG/PAPP-A > 7.94had a predictive ability for EOPE, and these cutoff values can help determine the use of aspirin at an earlier gestational age (GA).